Currently, cancer treatment involves surgical removal of the tumor followed by radiation therapy to arrest further growth of malignancy. Growing cancer cells overlap the surrounding healthy tissue. A clear demarcation of the two regions is vital during surgery. The detection and accurate imaging of the cancerous part is a major challenge faced by doctors. Nanotechnology-based tools may help doctors overcome this challenge in the future.
A new and emerging line of treatment is seeking solutions with nanotechnology-based ‘theranostic’ tools – a combined diagnosis and therapy. Such a system can detect, demarcate and treat the malignancy at the cancer site itself.
An interdisciplinary team of researchers from India and America has developed one such Nanotool that shows potential in precise imaging and treatment of tumors. Preliminary results on diseased animals indicate that the probe is useful as an in-situ guiding tool during surgery. The low-level laser used in this study not only guides ablation but also generates sufficient heat in nanoparticles to mitigate the growth, minimizing harmful effects.
In this study, the team developed an imaging system to detect cancers by a synergistic combination of two imaging methods — Fluorescence scanning and Surface-Enhanced Raman Scattering (SERS). The first method outlines the cancer region, while the second one gives a precise definition of the growth area.
Fluorescence imaging is done by exciting a fluorophore – an element that emits light when exposed to a specific laser and acts as a marker. Whereas, the basis of SERS imaging lies in detecting optical vibrations of ‘Raman photons’ that emit unique, fingerprint-like spectra of light. Raman scattering provides sharper images compared to fluorescence. A single fluorophore was used to capture both types of images.
The Nanoprobe is designed to permeate into spongy, porous cancer cells, while they do not pass through the denser, healthy tissue. When the region is irradiated with a near-infrared laser, the fluorescence camera detects the tumor. Simultaneously, the Raman imager captures the fluorophore’s Raman scattering, which gives the outline of the tumor tissue on a microscopic level.
Photothermal treatment done with the same laser which has high tissue penetration destroys tumor cells through localized heat generated in nanoparticles.
The crux of the research lies in the novel design of a multi-layered Nanoprobe derived from a conventionally used gold Nanoprobe that carries the fluorophore. The distance between the gold surface and the fluorophore element plays a crucial role in determining the excitation frequency and the intensity of the emitted light to capture the Raman Image.
Instead of directly loading the fluorophore on the gold nanoparticle, the team chose a DNA sequence as the carrier element. This way they could program and optimize the distance for best results. An added advantage was the biocompatibility of DNA, which reduced potential toxicity concerns.
“We used the classical molecular dynamics simulation technique and computationally modeled to verify which fluorophore-tagged DNA sequence can serve this purpose. From the simulations, we found that a particular fluorophore showed a strong affinity to a gold nanoparticle. From this, we selected a favorable DNA sequence and derived an optimal design,” explained Dr. Jagannath Mondal, who was involved in the simulation sequencing of the probe, while speaking to India science Wire.
By using programmable parameters, the fluorophore was loaded on the DNA and placed on a gold Nanorod core. Further, a layer of silver was added, which enhanced the signal intensity of the probe. A glass encapsulation ensured the protection of the probe called Fluorescence -Raman bimodal Nanoparticles (FRNPs).
“The strength of our design lies in the DNA-based design of optimized FRNPs, which offers effective fluorescence and Raman modalities that can be detected at very low concentrations. The low limit of detection enables efficient and high-resolution dual imaging of cancer for both internal and external study of the tissue,” said Dr. Suchetan Pal, first author of the study.
Standard laboratory tests confirmed biocompatibility of FRNP. When tested in animals with cancers, there was no adverse reaction in major organs. Animal studies were performed on two high mortality rate models of breast and ovarian cancer.
The FRNP was injected intravenously into the bloodstream and was found to reach the target in 2-3 hours. The nanoparticles permeated into cancer cells while leaving healthy tissue unaffected. The area was then irradiated with 785nm near-infrared laser. The FRNPs illuminated cancerous growth and its margins.
Dr. Moritz Kircher, Director, Molecular Cancer Imaging Facility at Dana-Farber Cancer Institute, and the lead researcher of the study told India Science Wire that, “using this real-time fluorescence and ultra-sensitive Raman images, we could precisely target the tumor tissue; Photothermal treatment resulted in successful nonsurgical and non-invasive cancer treatment.”
The design uses a low-level laser for Photothermal treatment – one that is used commercially in laser hair removal treatments. “This offers to eliminate exposure to high radiations that are in use currently, and thereby to prevent the associated adverse effects,” added Dr. Pal.
After long-term toxicity tests, the team plans pre-clinical and clinical studies.
The research team included Suchetan Pal (IIT, Bhilai); Angana Ray and Jagannath Mondal (TIFR, Hyderabad); Moritz F Kircher, Chrysafis Andreou, Masatomo Maeda, Naxhije Berisha, Jiang Yang, Hsiao-Ting Hsu and Anton Oseledchyk (Memorial Sloan Kettering Cancer Center, New York); Yadong Zhou & Shengli Zou (University of Central Florida); Ricardo Toledo-Crow (City University of New York); Tatini Rakshit( New York University) and Marek Wlodarczyk (City University of New York). The results were published in Nature Communications. (India Science Wire)
If you liked this article, then please subscribe to our YouTube Channel for the latest Science & Tech news. You can also find us on Twitter & Facebook.
